Analyzing Lymphoma Development and Progression Using HDACi in Mouse Models

• DOI: 10.1007/978-1-0716-2788-4_1
• Publication Date: 2022-10-18T13:04:40Z
• Authors: Eva-Maria Piskor; René Winkler; Christian Kosan
• Keywords: Histone Deacetylase Inhibitors; Histones; Mice; Disease Models, Animal; Lymphoma; Animals; Acetylation; Histone Deacetylases

Besides the physiological role of histone deacetalylases in maintaining normal cellular integrity, the acetylation landscape is changed in cancer cells, which has been implicated as a potential target in cancer therapy. The overexpression of certain HDACs correlates with specific cancer types. Therefore, the development of specific HDAC inhibitors may extend the therapeutic strategy for cancer therapy. Here, we describe how to investigate the therapeutic potential of specific HDACi by treatment in a mouse model for B-cell lymphoma, exemplified by the HDAC6 inhibitor Marbostat-100.